Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media involving Brainomix found in HSH's search of the last 24 months. Feb 2026: the company raised a further £4.8m, taking its Series C to £18.8m, to fund US expansion.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents, regulator action or published product vulnerabilities involving Brainomix found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
No recalls, safety notices or warning letters involving Brainomix products found in HSH's search of the last 24 months.
Contract delivery, go-lives, terminations and disputes.
No contract terminations, disputes or troubled implementations involving Brainomix found in HSH's search of the last 24 months. A government-commissioned evaluation across 26 NHS sites reported higher thrombectomy rates at sites using Brainomix 360 Stroke (May 2024, outside the window).